[
  {
    "ts": "2026-02-23T02:23:49+00:00",
    "headline": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
    "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3958fca3-186b-37b8-b756-2311c4075b52",
      "content": {
        "id": "3958fca3-186b-37b8-b756-2311c4075b52",
        "contentType": "STORY",
        "title": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has […]",
        "pubDate": "2026-02-23T02:23:49Z",
        "displayTime": "2026-02-23T02:23:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-takes-neutral-stance-gilead-022349658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BCS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:15:41+00:00",
    "headline": "Gilead to acquire Arcellx for $7.8 billion",
    "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
    "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e7d81dc8-c589-3573-99c8-7a644ef8bca0",
      "content": {
        "id": "e7d81dc8-c589-3573-99c8-7a644ef8bca0",
        "contentType": "STORY",
        "title": "Gilead to acquire Arcellx for $7.8 billion",
        "description": "",
        "summary": "Feb 23 () - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy ​developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.",
        "pubDate": "2026-02-23T11:15:41Z",
        "displayTime": "2026-02-23T11:15:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9",
          "originalWidth": 800,
          "originalHeight": 489,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V8FcAZ2HZF4nFOT4yy2xaw--~B/aD00ODk7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9.cf.webp",
              "width": 800,
              "height": 489,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VLfrg2QcYqhyDCV5I9n6zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4d1704d0b159fd01bb66e5955f523af9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-acquire-arcellx-7-8-111541314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:01:00+00:00",
    "headline": "Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel",
    "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
    "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b63a1407-0fa9-31b6-b99c-6abe13bf4b4e",
      "content": {
        "id": "b63a1407-0fa9-31b6-b99c-6abe13bf4b4e",
        "contentType": "STORY",
        "title": "Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel",
        "description": "",
        "summary": "FOSTER CITY, Calif. & REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur",
        "pubDate": "2026-02-23T11:01:00Z",
        "displayTime": "2026-02-23T11:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5endfg_bxOmc33HQNN4A9Q--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6zLN6Ivo8K2g33MEQDLvTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/db916ee653d5bb61381083eaa5da9a52.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]